Source - SMW
Allergy Therapeutics said Tuesday its house-dust mite immunotherapy demonstrated highly significant symptom improvement in a clinical trial.  

In the observational study conducted in 10 sites across Spain, 141 patients were evaluated and demonstrated a 43% decrease in combined symptom medication score compared with baseline after one year, the company said.

The company's latest research at EAACI included an overview of the early-phase pre-clinical developments for the group's planned recombinant peanut vaccine and a discussion of the results of a non-interventional study investigating rapid up-dosing of tree sublingual immunotherapy.

'The positive new data on our modified house-dust mite immunotherapy and our recent announcement on the success of our Grass G205 dose-finding clinical study confirms that our novel allergen-specific immunotherapies are formulated to the optimal strength, and we believe Allergy Therapeutics has the potential to transform allergy treatment with optimised-dose, well-characterised, aluminium-free, convenient products,’ said Manuel Llobet,' Chief Executive Officer. 

At 9:26am: (LON:AGY) Allergy Therapeutics PLC share price was 0p at 25.5p

Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.